# Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

> **NCT03045341** · PHASE2,PHASE3 · COMPLETED · sponsor: **Yale University** · enrollment: 136 (actual)

## Conditions studied

- Binge-eating Disorder
- Obesity

## Interventions

- **DRUG:** NB medication (Naltrexone Bupropion combination)
- **BEHAVIORAL:** Behavioral Weight Loss (BWL) counseling
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03045341
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-27
- **Primary completion:** 2021-07-23
- **Final completion:** 2022-12-16
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2023-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03045341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03045341, "Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03045341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*